Evaluation of atezolizumab immunogenicity: Clinical pharmacology (part 1)
Abstract Baseline patient characteristics and prognostic factors are important considerations in oncology when evaluating the impact of immunogenicity on pharmacokinetics (PK) and efficacy. Here, we assessed the impact of anti‐drug antibodies (ADA) on the PK of the immune checkpoint inhibitor atezol...
Na minha lista:
| Principais autores: | , , , , , , , , , , , , , |
|---|---|
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Wiley
2022-01-01
|
| 叢編: | Clinical and Translational Science |
| 在線閱讀: | https://doi.org/10.1111/cts.13127 |
| 標簽: |
沒有標簽, 成為第一個標記此記錄!
|